Current Treatments for Generalized Pustular Psoriasis: A Narrative Summary of a Systematic Literature Search

• Published in: Dermatology and therapy 2024-09, Vol.14 (9), p.2331-2378
• Main Authors: Puig, Lluís, Fujita, Hideki, Thaçi, Diamant, Zheng, Min, Hernandez Daly, Ana Cristina, Leonardi, Craig, Lebwohl, Mark G., Barker, Jonathan
• Format: Article
• Language: English
• Subjects: Autoinflammation; Care and treatment; Dermatology; Generalized pustular psoriasis; GPP; Health aspects; IL-36R inhibitor; Internal Medicine; Medical research; Medicine; Medicine & Public Health; Medicine, Experimental; Methods; Neutrophilic dermatoses; Oral and Maxillofacial Surgery; Plastic Surgery; Psoriasis; Quality of life; Quality of Life Research; Review
• ISSN: 2193-8210; 2190-9172
• DOI: 10.1007/s13555-024-01230-z

Generalized pustular psoriasis (GPP) is a rare, chronic and potentially life-threatening autoinflammatory skin disease characterized by widespread eruption of sterile pustules, with or without systemic inflammation. GPP can significantly reduce patients’ quality of life (QoL). Several therapeutic approaches have been described in the literature, but there is no consensus on optimal treatment. In this review, we summarize published literature on efficacy, safety and QoL outcomes associated with current treatment of GPP with both approved and non-approved products. Embase and MEDLINE databases were searched (1980–September 2023). A search protocol was designed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and registered on the PROSPERO database (CRD42021215437). Details on publication, population, intervention, efficacy, safety and QoL were captured and checked by independent reviewers. In total, 118 publications were included, with only 19% of publications reporting on the results of clinical trials. Treatment modalities reported for GPP included non-biologic systemic therapies such as retinoids, cyclosporine and methotrexate, topical agents, biologics and small molecules, among others. Results were highly heterogeneous and methodological quality was very low, with only the interleukin-36R inhibitor spesolimab reporting results from placebo-controlled randomized trials; based on this, spesolimab is now approved for GPP treatment in regions including the USA, Japan, China, the EU and several other countries. Some other biologics are approved exclusively in Japan and Taiwan for the treatment of GPP based on open-label studies with small patient numbers in lieu of double-blind studies. Non-standardization of clinical outcomes across studies remains a major hurdle in reaching a consensus on optimal treatment. However, recently trials have been conducted using well-defined, disease-specific endpoints to evaluate GPP-targeted treatments, which will hopefully advance patient care. In conclusion, this review highlights the need for prospective randomized studies with GPP-specific endpoints to determine the optimal treatment strategy. Plain Language Summary Generalized pustular psoriasis (GPP) is a rare, chronic skin condition characterized by painful, sterile pustules that can occur all over the body. These pustules may also be accompanied by systemic inflammation, which can lead to serious health comp